Please ensure Javascript is enabled for purposes of website accessibility

Why BeyondSpring Is Plunging Today

By Prosper Junior Bakiny – Jun 19, 2020 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a public offering of common stock.

What happened

Shares of BeyondSpring (BYSI -0.51%) -- a clinical-stage biopharmaceutical company -- are down by 18.1% as of 11:26 a.m. EDT on Friday, following the drugmaker's announcement of the pricing of a public offering of ordinary shares. With the company set to dilute existing shareholders, it isn't surprising that its stock plummeted today.

So what

BeyondSpring first announced it was initiating a public offering of ordinary shares on Thursday. Today the company announced that it was selling 1,930,000 ordinary shares for $13 per share. BeyondSpring is giving underwriters a 30-day option to purchase an additional 289,500 shares. Also, the company said that it would sell 384,615 shares to an investment firm called Decheng Capital (and its affiliates) in a separate private offering. BeyondSpring expects the proceeds from this public offering to total about $30.1 million. Note that BeyondSpring's shares closed at about $16.60 on Thursday. At writing, the company's shares are down to $13.72 apiece.

Five downward pointing arrows on a blackboard.

Image source: Getty Images.

Now what

BeyondSpring currently has no approved products on the market, and the company does not generate any revenue. During the first quarter, BeyondSpring reported a net loss of $16.7 million and a cash balance of $24.9 million as of March 31. The healthcare company intends to use the proceeds from its public offering of ordinary shares to "support the commercialization of Plinabulin," its most advanced pipeline candidate.

Plinabulin is being investigated for the prevention of chemotherapy-induced neutropenia (CIN) in combination with Neulasta, a bone marrow stimulant marketed by Amgen (AMGN -1.11%). BeyondSpring plans on submitting a New Drug Application to the U.S. Food and Drug Administration for Plinabulin by year end. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BeyondSpring Inc. Stock Quote
BeyondSpring Inc.
BYSI
$0.97 (-0.51%) $0.01
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$228.41 (-1.11%) $-2.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.